On the other hand, subjects with baseline adiponectin in the tertile 3 had a decreased risk of subsequent gynecological cancer as compared with those in the tertile 1 (OR = 0.07, 95% CI = 0.01–0.62, p = 0.016 and OR = 0.31, 95% CI = 0.07–1.30, p = 0.108 for UCC and OVC, respectively). This evidence concerns the gene ADIPOQ and female reproductive organ cancer.